TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12759717
Drug: Isoprenaline infusion
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline infusion (3.5‐35 ng/kg/min)
Study: 12759717
Drug: Terbutaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline infusion (25‐150 ng/kg/min)
Study: 12759717
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (20‐160 ng/kg/min)
Study: 10793322
Drug: Donepezil (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (initially 3 mg per day, increased to 5, 7, and 10 mg per day as needed)
Study: 22047597
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 670-nm laser irradiation, 40 mW, 1.6 J, 2.04 J/cm(2), 51 mW/cm(2) per blister in the prodromal stage and 4.8 J in the crust and secondarily infected stages, plus 1.2 J at the C2-C3 vertebrae
Study: 22047597
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy including acyclovir cream or tablets
Study: 15842517
Drug: Placebo (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (120 mg three times daily)
Study: 11742909
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP), 1,000 microg/d for 4 months
Study: 11742909
Drug: Inhaled bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilator therapy (control group)
Study: 9031898
Drug: LAM (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM (lansoprazole 30 mg once a day for 1 week, azithromycin 500 mg once a day for 3 days, metronidazole 250 mg twice a day for 3 days)
Study: 3090600
Drug: Scopolamine 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.9 mg
Study: 22442959
Drug: Cycloferon (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloferon (500 mg)
Study: 19038698
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (abstinence plus vitamins)
Study: 19038698
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (abstinence plus vitamins) in subgroup of 26 subjects with mild alcoholic hepatitis
Study: 7848119
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin placebo (control group)
Study: 10493207
Drug: Beta-carotene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (50 mg on alternate days)
Study: 7935030
Drug: Conjugated estrogens,
Normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens, 0.625 mg daily
Study: 29543510
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy group (PTG)
Study: 20007824
Drug: Peripheral drusen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral drusen associated with CFHY402H (CC versus TT genotypes)
Study: 20007824
Drug: Macular drusen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macular drusen >63 microm associated with CFHY402H (CC versus TT genotypes)
Study: 18387797
Drug: Budesonide Turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Turbuhaler 100 microg twice daily
Study: 18387797
Drug: Budesonide Turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Turbuhaler 400 microg twice daily
Study: 18387797
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 mg/day (early treatment group)
Study: 18387797
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 mg/day (established symptoms)
Study: 10327094
Drug: Outpatient or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient or day hospital therapy (control group)
Study: 7562021
Drug: alpha 2a-interferon
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha 2a-interferon (alpha 2a-INF) in combination with vinblastine
Study: 7322956
Drug: Indapamide treatment
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide treatment for 1 week
Study: 7322956
Drug: Indapamide treatment
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide treatment for 6 weeks
Study: 7322956
Drug: Indapamide treatment
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide treatment for 2, 4, and 6 weeks
Study: 6428643
Drug: Oral Pancreatic
Normalized name: pancreatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Pancreatic Function Test
Study: 6428643
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CT with either ultrasound or oral pancreatic function test
Study: 30536572
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump use
Study: 22836303
Drug: PerMIT S‐warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PerMIT S‐warfarin plasma concentration model
Study: 20434827
Drug: Mifepristone/misoprostol (MM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone/misoprostol (MM) - 200 mg mifepristone orally followed by 400 microg misoprostol vaginally after 36-48 hours, with up to three additional doses of 400 microg misoprostol every 12 hours
Study: 20434827
Drug: Intra-amniotic injection
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic injection of ethacridine lactate (EL) - 100 mg ethacridine lactate
Study: 10550131
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Double the dose and intensity of cyclophosphamide (4 courses)
Study: 10550131
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Same dose of cyclophosphamide as in Group 1 (2 courses, intensified)
Study: 10550131
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: Double the dose of cyclophosphamide (intensified and increased)
Study: 10550131
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (B-22 standard therapy)
Study: 7541637
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 Mio KIU loading dose before sternotomy, followed by 0.5 Mio KIU/h infusion until end of surgery; 2 Mio KIU added to priming volume)
Study: 2192440
Drug: Ceftazidime (CAZ)
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime (CAZ) 150 mg/kg/day + Flucloxacillin (FLUC) 50 mg/kg/day
Study: 2192440
Drug: Piperacillin (PIP)
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin (PIP) 200 mg/kg/day + Flucloxacillin (FLUC) 50 mg/kg/day
Study: 25655792
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care for cancer: optimized usual drug therapies and strengthening of self-care
Study: 22856633
Drug: MP29-02 (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP29-02 (intranasal formulation of azelastine hydrochloride and fluticasone propionate)
Study: 17515294
Drug: Devasid 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Devasid 250 mg/5 ml (test preparation)
Study: 17515294
Drug: 375 mg/7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg/7.5 ml (reference preparation)
Study: 17515294
Drug: Devasid (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Devasid (test preparation)
Study: 10740332
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of 17beta‐oestradiol continuously combined with 1 mg of norethisterone acetate (E2+NETA)
Study: 10740332
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of piperazine oestrone sulphate plus 0.7 mg of norethisterone (highEP)
Study: 10740332
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg of piperazine oestrone sulphate plus 0.35 mg of norethisterone (lowEP)
Study: 8476831
Drug: Prophylactic progestogen
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic progestogen in addition to conventional therapy
Study: 29122372
Drug: Sufentanil sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil sublingual tablet 30mcg (SST 30mcg) - single-dose cohort
Study: 29122372
Drug: Sufentanil sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil sublingual tablet 30mcg (SST 30mcg) - multiple-dose cohort
Study: 29122372
Drug: Sufentanil sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil sublingual tablet 30mcg (SST 30mcg) - combined cohorts
Study: 23429918
Drug: Sildenafil 20
Normalized name: sildenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 20 mg three times daily
Study: 7083734
Drug: Flurbiprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (50 mg)
Study: 18443390
Drug: Parent-only cognitive
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-only cognitive behavioral therapy (CBT)
Study: 12942707
Drug: Increased colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased colchicine dose in 26 randomly chosen patients with no attacks in the last year.
Study: 10765123
Drug: Gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m(2)) followed by 5‐FU (600 mg/m(2)) weekly for 3 weeks of every 4
Study: 3897559
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of praziquantel 40 mg/kg bodyweight
Study: 3897559
Drug: Divided dose
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dose of praziquantel 2 X 20 mg/kg given 4‐6 h apart
Study: 31176295
Drug: Pre-treatment resting-state
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment resting-state functional connectivity (rsFC)
Study: 29223508
Drug: Budesonide/Formoterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/Formoterol combination via dry powder inhalers
Study: 29223508
Drug: Inhaled FOR
Normalized name: Gas for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled FOR
Study: 29223508
Drug: Inhaled BUD
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled BUD
Study: 26847320
Drug: Robot active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot active assisted therapy (RT)
Study: 26847320
Drug: Classical occupational
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical occupational therapy (OT)
Study: 10963640
Drug: FEC 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 75 (11 cycles of fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) every 21 days)
Study: 10963640
Drug: FEC 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC 100 (four cycles of epirubicin 100 mg/m(2) then eight cycles of epirubicin 50 mg/m(2))
Study: 7534423
Drug: Raclopride at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raclopride at 12 mg/day
Study: 7534423
Drug: Raclopride at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raclopride at 2 mg/day
Study: 7534423
Drug: Raclopride at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raclopride at 6 mg/day
Study: 7534423
Drug: Haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol at 15 mg/day
Study: 3362801
Drug: Nicotine chewing
Normalized name: nicotine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine chewing gum (brief individual treatment)
Study: 27235824
Drug: Semantic priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Semantic priming with healthy body image words (e.g., 'slim', 'fit')
Study: 15489085
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (antiplatelet plus moderate-intensity anticoagulation)
Study: 11181493
Drug: Busulfan at
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan at a dose of 16 mg/kg
Study: 9692701
Drug: Liquid Gaviscon
Normalized name: Gaviscon Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid Gaviscon (20 ml dose)
Study: 2196536
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 10 mg orally
Study: 2196536
Drug: Acetaminophen 600
Normalized name: acetaminophen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 600 mg plus codeine 60 mg orally
Study: 19537357
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin (Exubera) three times daily prior to meals
Study: 19537357
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin glargine (Lantus) once daily
Study: 30333269
Drug: Solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin succinate 5 mg
Study: 15317830
Drug: Solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin succinate 10 mg
Study: 15317830
Drug: Solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin succinate 20 mg
Study: 15317830
Drug: Solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin succinate 30 mg
Study: 15317830
Drug: Solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin succinate 100 mg
Study: 15317830
Drug: Solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin succinate (various doses)
Study: 10392868
Drug: Moxonidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.6 mg
Study: 10945312
Drug: Moxonidine 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.9 mg
Study: 10945312
Drug: Moxonidine 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 1.2 mg
Study: 9243349
Drug: 9-cis-retinoic acid
Normalized name: 9-cis-retinoic acid
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-cis-retinoic acid (5 mg, 15 mg, 40 mg, 80 mg, 150 mg)
Study: 9243349
Drug: 9-cis-retinoic acid
Normalized name: 9-cis-retinoic acid
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-cis-retinoic acid (various doses)
Study: 7954483
Drug: moclobemide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide (300 mg daily)
Study: 7954483
Drug: maprotiline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: maprotiline (75 mg daily)
Study: 3118861
Drug: Enprostil (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil (35 micrograms capsule)
Study: 3118861
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg tablet)
Study: 22995653
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg, once daily) plus prednisone (5 mg, orally twice daily)
Study: 22995653
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus prednisone (5 mg, orally twice daily)
Study: 18953051
Drug: BMC-SN and
Normalized name: SN-38
DrugBank: SN-38 (DB05482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMC-SN and PBL-SN in combination
Study: 15683890
Drug: Buccal bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal bonding
Study: 12841540
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium gluconolactate administration (1 g)
Study: 10391666
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg twice a day for 7 days)
Study: 8853756
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg once daily (L15)
Study: 8853756
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily (L30)
Study: 8853756
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg b.d. (R600)
Study: 1737544
Drug: Glipizide (11.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (11.9 mg)
Study: 1737544
Drug: Glyburide (8.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (8.4 mg)
Study: 1737544
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Glipizide and Glyburide)
Study: 6336862
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gentamicin (80 mg) and clindamycin (600 mg) administered intravenously, three doses daily for 2 days.
Study: 6336862
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gentamicin (80 mg) and metronidazole (500 mg) administered intravenously, three doses daily for 2 days.
Study: 29893422
Drug: Standard itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard itraconazole pulse therapy (200 mg twice per day, 1 week each month for three pulses)
Study: 29893422
Drug: Long-term pulse
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term pulse therapy (200 mg twice per day, 1 week each month for six pulses)
Study: 29893422
Drug: Low-dose and
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose and long-term pulse therapy (200 mg/d, 1 week per month for six pulses)
Study: 24445389
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL 0.5% levobupivacaine
Study: 19329013
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL 2% lidocaine
Study: 24445389
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL 0.9% saline (control group)
Study: 19436684
Drug: General physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: General physical training (GPT); walking and stair climbing exercises; trained daily for 30 minutes for eight weeks.
Study: 19436684
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT); targeted breathing through inspiratory resistances; trained daily for 30 minutes for eight weeks.
Study: 17564015
Drug: Indapamide retard
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide retard (1.5 mg/day)
Study: 17564015
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg/day)
Study: 14757271
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 40 mg plus estradiol valerate 2 mg
Study: 14757271
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus estradiol valerate 2 mg
Study: 11848548
Drug: Sucralfate gel
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate gel (1 gr.) applied 3 times daily
Study: 11848548
Drug: Sucralfate gel
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate gel (1 gr.)
Study: 8163718
Drug: OPC-18790 (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-18790 (0.05, 0.1, 0.2, or 0.4 mg/kg intravenous dose)
Study: 8163718
Drug: OPC-18790 (1-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-18790 (1-hour infusion of 0.5, 1.0, 2.5, 5.0, 10.0, or 15.0 micrograms/kg/minute)
Study: 3283919
Drug: Famotidine, 40
Normalized name: Famotidine, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine, 40 mg at night
Study: 30031553
Drug: Mechanical Diagnosis
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical Diagnosis and Therapy (MDT)
Study: 27488071
Drug: Low-dose rAAV.sFlt‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose rAAV.sFlt‐1 (1 × 10 vector genomes)
Study: 27488071
Drug: High-dose rAAV.sFlt‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rAAV.sFlt‐1 (1 × 10 vector genomes)
Study: 24477462
Drug: 1 %
Normalized name: oxygen 1 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 % terbinafine film-forming solution (FFS)
Study: 22781292
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rh‐Endostatin (7.5 mg/m(2), d1‐d14) with neoadjuvant DE regimen (docetaxel: 75 mg/m(2), d1, epirubicin: 75 mg/m(2), d1)
Study: 22781292
Drug: Neoadjuvant DE
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant DE regimen (docetaxel: 75 mg/m(2), d1, epirubicin: 75 mg/m(2), d1) alone